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ABSTRACT
Accumulation of myofibroblasts is a hallmark of renal fibrosis. A significant proportion of myofibroblasts
has been reported to originate via endothelial-mesenchymal transition. We initially hypothesized that
exposing myofibroblasts to the extract of endothelial progenitor cells (EPCs) could reverse this transition.
Indeed, in vitro treatment of transforming growth factor-b1 (TGF-b1)-activated fibroblasts with EPC extract prevented expression of a-smooth muscle actin (a-SMA); however, it did not enhance expression of
endothelial markers. In two distinct models of renal fibrosis—unilateral ureteral obstruction and chronic
phase of folic acid-induced nephropathy—subcapsular injection of EPC extract to the kidney prevented
and reversed accumulation of a-SMA-positive myofibroblasts and reduced fibrosis. Screening the composition of EPC extract for cytokines revealed that it is enriched in leukemia inhibitory factor (LIF) and
vascular endothelial growth factor. Only LIF was capable of reducing fibroblast-to-myofibroblast transition of TGF-b1-activated fibroblasts. In vivo subcapsular administration of LIF reduced the number of
myofibroblasts and improved the density of peritubular capillaries; however, it did not reduce
the degree of fibrosis. A receptor-independent ligand for the gp130/STAT3 pathway, hyperinterleukin-6 (hyper-IL-6), not only induced a robust downstream increase in pluripotency factors
Nanog and c-Myc but also exhibited a powerful antifibrotic effect. In conclusion, EPC extract prevented and reversed fibroblast-to-myofibroblast transition and renal fibrosis. The component of
EPC extract, LIF, was capable of preventing development of the contractile phenotype of activated
fibroblasts but did not eliminate TGF-b1-induced collagen synthesis in cultured fibroblasts and models
of renal fibrosis, whereas a receptor-independent gp130/STAT3 agonist, hyper-IL-6, prevented fibrosis.
In summary, these studies, through the evolution from EPC extract to LIF and then to hyper-IL-6, demonstrate the instructive role of microenvironmental cues and may provide in the future a facile strategy
to prevent and reverse renal fibrosis. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:992–1005
2016;5:1–14

SIGNIFICANCE
IGNIFICANCESTATEMENT
This study continued exploration of the beneficial effects of endothelial progenitor cells (EPCs) and their
secretory products. Remarkable prevention of renal fibrosis was documented after treatment with EPC
extract in two different fibrogenic models of chronic kidney disease. One of the products of EPC is leukemia inhibitory factor, which itself activated the STAT3 pathway and mitigated formation of myofibroblasts, whereas a more potent gp130/STAT3 agonist, a fusion protein hyper-IL-6, also prevented renal
fibrosis. This line of investigations represents an early attempt to complement progenitor cell transplantation with treatments based on the administration of secretory products released by these cells.

INTRODUCTION
Transcription factor-mediated reprogramming
of fibroblasts to mature specialized cells has
captured significant attention since the description of induced pluripotency by Takahashi and
Yamanaka [1]. Successive studies, each using
the set of defined transcription factors, produced

data on reprogramming of fibroblasts to neuronal cells, cardiomyocytes, or hematopoietic stem
cells [2–4]. Reprogramming has also been shown
in vivo by the local delivery of transcription factors for therapeutic purposes [5].
In parallel with these spectaculardevelopments,
an intriguing technology for cell reprogramming
has emerged by exposing reversibly permeabilized

STEM CELLS TRANSLATIONAL MEDICINE 2017;6:992–1005
www.StemCellsTM.com
2016;5:1–14 www.StemCellsTM.com

c 2016 Press
The Authors
O
©AlphaMed
2016
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

ID: srinivasanv Time: 20:00 I Path: //chenas03/Cenpro/ApplicationFiles/Journals/Wiley/SCTM/Vol00603/170037/Comp/APPFile/JW-SCTM170037

2Matsumoto, Xavier, Chen et al.

cultured somatic cells to extracts obtained from lineage-dissimilar
cells. This approach has produced somatic cells reprogrammed with
the extracts from mammalian oocytes, human T-lymphocytes, or
neuronal precursors [6–10].
Tissue fibrosis, the common final outcome of diverse chronic
diseases, is a result of conversion of multiple resident cells, such
as fibroblasts and fibrocytes, pericytes, and epithelial, or endothelial cells, into myofibroblasts [11–15]. The accumulation of
myofibroblasts leads to excessive matrix deposition and fibrotic
distortion of tissue architecture, eventuating in the loss of organ
function. Given that a sizable proportion of fibrogenic myofibroblasts has been reported to be generated by the process of
endothelial-to-mesenchymal transition [15], we initially inquired
whether this process could be reversed. The first experimental
evidence that this is possible has recently been presented in
the case of myocardial ischemia [16].
Toward this end, we attempted to reprogram myofibroblasts to
endothelial cells using cell-free extract obtained from murine endothelial progenitor cells, both in vitro and in vivo. We used models of
renal fibrosis, unilateral ureteral obstruction, and chronic phase of
folic acid-induced nephropathy to monitor the extent of fibrosis
after injection of cell extract. The described procedures resulted
in an approximately 50% reduction of fibrosis by preventing
myofibroblast formation rather than conversion of myofibroblasts to endothelial cells. Leukemia inhibitory factor (LIF) was
found to represent a component of the extract partially responsible for prevention and reversal of myofibroblast formation. A
receptor-independent ligand activating gp130/STAT3 signaling,
a fusion protein hyper-interleukin-6 (hyper-IL-6), was able to
prevent fibrosis in a process that temporarily induced pluripotency transcription factors.

MATERIALS AND METHODS
Experimental Animals
All animal studies were performed in accordance with the National Institutes of Health (NIH) NIH Guide for the Care and Use
of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee at New York Medical College.
a-Smooth muscle actin (SMA)-green fluorescent protein (GFP)
transgenic mice on a C57BL/6J background were obtained
from Dr. Ivo Kalajzic (University of Connecticut Health Center,
Farmington, CT). Mice were originally developed by Dr. Jen-Yue
Tsai (National Eye Institute/NIH) and carry a regulatory sequence
of aSMA gene spanning 1074 base pair (bp) of the 59-flanking region,
the transcription start site, 48 bp of exon 1, the 2.5-kbp intron 1, and
the 15-bp exon 2 of mouse a-SMA. GFP is specifically expressed in
both vascular and nonvascular smooth muscle cells [17, 18]. Studies
were performed in 20-week-old aSMA-GFP transgenic mice or wildtype siblings. Mice were housed in the animal care facility of New
York Medical College (25°C, 50% humidity, 12-hour dark/light cycle)
and had free access to food and water.

Disease Models
The unilateral ureteric obstruction (UUO) procedure was performed according to the standard protocol [19]. Mice were anesthetized with isoflurane and placed in the lateral position under
body temperature control. Surgery was performed through a left
flank incision. The ureter was identified and tied at the level of the
lower pole of the kidney with two separate silk ties.
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Mice were injected with EPC extract diluted 1:2 (10 ml) or
buffer subcapsularly into the lower pole of UUO kidney on
day 0. Mice were euthanized on day 14. At the end of the study,
the mice were anesthetized, blood was collected by cardiac
puncture, and kidneys were excised. Renal tissue was divided
and portions were snap-frozen in liquid nitrogen or fixed in
4% paraformaldehyde/phosphate-buffered saline (PBS).
To produce folic acid-induced nephropathy (FAN), mice were
intraperitoneally injected with folic acid (250 mg/kg) in 0.3 M
NaHCO3. EPC extract (10 ml) was injected subcapsularly into
the left kidney and buffer (10 ml) was injected into the right kidney
on day 56 after induction of FAN. Mice were euthanized on day
84 after induction of FAN. At the end of the study, mice were anesthetized, blood was collected by cardiac puncture, and kidneys
were excised. Renal tissue was divided and portions were snapfrozen in liquid nitrogen or fixed in 4% paraformaldehyde/PBS.

Isolation and Culture of Primary Renal Fibroblasts
Fibroblasts were isolated from kidneys dissected from 8-week-old
a-SMA-GFP mice, according to the previously published protocol [20]. Briefly, cells were seeded onto a 1% gelatin-coated
Petri dish, covered with 4 ml of Dulbecco’s modified Eagle’s medium (DMEM; American Type Culture Collection, Manassas, VA,
https://www.atcc.org) containing 20% fetal bovine serum (FBS),
and incubated at 37°C in a humidified 5% CO2 atmosphere. The primary cultures used in this study were between passage (P) 2 and P3.
Cells were treated with EPC extract, recombinant mouse LIF
(100 pg/ml–10 ng/ml) (Thermo Fisher Scientific Life Sciences,
Waltham, MA, http://www.thermofisher.com), vascular endothelial growth factor (VEGF) (1 ng/ml), transforming growth
factor (TGF)-b1 receptor blocker (SB431542) (5 mM) (Tocris Bioscience, Bristol, UK, https://www.tocris.com), recombinant human TGF-b1 (5 ng/ml) (R&D Systems, Minneapolis, MN, http://
www.rndsystems.com), or recombinant human TGF-b1 (5 ng/ml)
in the presence of EPC extract or LIF for 4 days.
Alternatively, to isolate primary renal fibroblasts, single-cell suspension from mouse kidney was prepared by using enzymatic digestion with a mixture of collagenase H and collagenase/Dispase (Roche,
Basel, Switzerland, http://www.roche.com). Endothelial cells were
then depleted with magnetic Dynabeads (Thermo Fisher) coated
with rat anti-mouse CD31 antibody (BD Pharmingen, San Jose, CA,
http://www.bdbiosciences.com). The remaining cells were collected, resuspended in DMEM (supplemented with 10% FBS), plated
on 1% gelatin-coated 100-mm dishes, and cultured at 37°C in a CO2
incubator. Upon confluence, cells were subcultured in gelatin-coated
dishes at a 1:3 ratio and designated as passage 1 (P1). For experiments, the cells at P2 were used. The fibroblast origin of cultured cells
at P2 was confirmed with antibodies for platelet-derived growth
factor receptor- b, a2SMA, F4/80, and CD31. NIH3T3 fibroblasts
(American Type Culture Collection) were cultured in DMEM
(American Type Culture Collection) with 10% FBS. Cells were
treated with recombinant human TGF-b1 (5 ng/ml) (R&D Systems) for 5 days to induce myofibroblastic phenotype. Primary
renal fibroblasts and NIH3T3 fibroblasts were treated with
recombinant human TGF-b1 (5 ng/ml) alone or TGF-b1 with
EPC extract, LIF, or hyper-IL-6 for 6 hours, 24 hours, and 48 hours
for quantitative polymerase chain reaction analysis.
Additional studies were performed by using Oct4-GFP-reporter
fibroblasts obtained from transgenic mice expressing tamoxifeninducible Cre recombinase MerCreMer under the control of the
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endogenous Oct4 locus [21]. Oct4-GFP fibroblasts were cultured
in DMEM containing 13 penicillin/streptomycin, 1% nonessential amino acids, and 10% FBS at 37°C in 5% CO2; 1 mM 4 hydroxytamoxifen was added to the medium. The transgenic mice
contain the conditional MerCreMer cassette inserted in the
39 -untranslated region of the Oct4 locus and combined with
the dual membrane-bound fluorescent protein mTmG reporter.
Cre recombination occurs only in cells that are actively expressing Oct4 and when tamoxifen is present. In these cells, there is an
irreversible switch from expressing membrane-bound dTomato
to expressing membrane-bound enhanced GFP.
Embryonic mouse EPCs isolated from embryos at E7.5–E7.8 of
development were kindly provided by Dr. A. Hatzopoulos [22].
EPCs were plated on 0.1% gelatin-coated plates and maintained
at 37°C and 5% CO2 in DMEM culture medium containing 20%
heat-inactivated serum (55°C for 30 minutes; Thermo Fisher),
0.1 mmol/liter 2-mercaptoethanol, 1 mmol/liter modified Eagle’s
medium nonessential amino acids (Thermo Fisher), 100 U/ml
penicillin and 100 mg/ml streptomycin, 2 mmol/liter L-glutamine
(Thermo Fisher), and 2 mmol/liter HEPES, pH 7.5.

Preparation of EPC Extract
EPCs were trypsinized, washed in PBS and in cold lysis buffer (10 mM
HEPES, pH 8.2, 50 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, and
protease inhibitor cocktail), sedimented at 800g, and resuspended in
1 volume of cell lysis buffer. Cells were sonicated on ice in 250-ml aliquots until cells and nuclei were completely lysed, as judged by microscopical examination. The lysate was sedimented at 15,000g for
10 minutes at 4°C and the supernatant was divided into aliquots, frozen in liquid nitrogen, and stored for up to 6 months at 280°C [23].

Histologic and Immunofluorescence Studies
Tissues fixed in 4% paraformaldehyde/PBS were embedded in
paraffin and 4-mm-thick sections were stained with Masson’s trichrome. The extent of Masson’s trichrome-positive area was digitally quantified by using Photoshop (Adobe Systems, San Jose,
CA, http://www.adobe.com) and expressed as a percentage of
the total area. All histologic analyses were performed by two investigators without knowledge of the origin of the slides, and the
mean values were calculated.
For immunofluorescence studies, kidneys were fixed in 4%
paraformaldehyde overnight, transferred to PBS containing 30%
sucrose overnight, embedded in optimal cutting temperature medium (Tissue-Tek; Sakura Finetek U.S.A., Inc., Torrance, CA, http://
www.sakura-americas.com/) and cryosectioned (10-mm-thick sections). Sections were permeabilized with 0.3% Triton X-100 for 5
minutes, blocked with PBS-bovine serum albumin (BSA) (1%) for
1 hour, and stained with primary antibodies at 4°C overnight.
The primary antibodies were rat monoclonal antibody to CD31
(platelet endothelial cell adhesion molecule 1) (BD Pharmingen),
rabbit polyclonal antibody against a-SMA (Abcam, Cambridge,
MA, http://www.abcam.com), and rat monoclonal antibody to
F4/80 (eBioscience, San Diego, CA, http://www.ebioscience.com).
We used AlexaFluor 594 conjugated goat anti-rat (Thermo Fisher)
secondary antibodies, according to the manufacturer’s recommendations. Nuclei were counterstained with Hoechst 33342. Images
were obtained by using a compound Nikon microscope (TE-2000U;
Nikon, Tokyo, Japan, http://www.nikon.com/) equipped with a SPOT
digital camera (SPOT Imaging, Sterling Heights, MI, http://www.
spotimaging.com). At least five visual fields per specimen were
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analyzed for localization of endothelial and myofibroblast markers.
CD31-positive peritubular capillary density and the number of
a-SMA-positive cells were quantified by using a grid method (266
squares) applied to images acquired at 340 magnification.

Cytokine and Chemokine Analysis of EPC Extract
The concentration of a panel of 15 cytokines and chemokines in EPC
extract was measured with a Luminex IS100 analyzer and results
analyzed by using appropriate curve-fitting software (Luminex
100IS software version 2; Luminex Corp., Austin, TX, https://
www.luminexcorp.com/). The concentration of selected cytokines
and chemokines was measured by using a Milliplex map kit (EMD
Millipore Corp., Billerica, MA, http://www.emdmillipore.com). The
EPC extract or lysis buffer alone was used for cytokine/chemokine
analysis. Measurements were performed by using premixed antibody beads (Milliplex), according to manufacturer’s instructions,
and results were read by using Luminex-200 against a standard
curve. Quality controls were included in each assay.

Streptolysin O Permeabilization and Cell
Extract Treatment
Procedures followed our previously reported protocol [24]. Preliminary experiments showed that the optimal concentration of
streptolysin O (SLO) (Sigma-Aldrich, St. Louis, MO, http://www.
sigmaaldrich.com) for NIH 3T3 cells using a concentration of
400 ng/ml resulted in permeabilization efficiency of .80%, as
assessed by monitoring the uptake of a Mr 70,000 Texas redconjugated dextran (50 mg/ml; Thermo Fisher). Trypan blue exclusion assay showed that cell viability at this SLO concentration was
minimally affected. Briefly, NIH 3T3 cells were washed twice in cold
PBS and once in ice-cold Ca2+- and Mg2+-free Hank’s balanced salt
solution (Thermo Fisher) and divided into aliquots, and SLO was
added. Permeabilized cells were suspended in 100 ml of EPC extract containing an ATP-regenerating system (1 mmol/liter ATP,
10 mmol/liter creatine phosphate, and 25 mg/ml creatine kinase;
100 mmol/L GTP; all from Sigma-Aldrich), and 1 mmol/liter of nucleotide trisphosphate (Roche Diagnostics) and incubated for
1 hour at 37°C in a dry heat block with occasional agitation.
To reseal cell membranes, the cell suspension was diluted with
complete endothelial cell medium containing 2 mM CaCl2, and
cells were cultured in endothelial basal medium-2 (EBM-2) supplemented with growth supplements (Lonza, South Plainfield,
NJ, http://www.lonza.com). As a control, NIH 3T3 cells were cultured in EBM-2 supplemented with growth supplements.

Imaging of a-SMA-GFP cells
Primary renal fibroblasts obtained from wild-type or transgenic
mice were cultured on gelatin-coated eight-well culture slides
(Lab-Tek Chamber Slides, Thermo Fisher) and fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.3% Triton
X-100 for 5 minutes, and blocked with 1% BSA/PBS for 1 hour.
Cells were stained with anti-CD144 (VE-Cadherin) (BD Pharmingen),
followed by incubation with secondary antibodies. Time-lapse images were acquired by using IncuCyte Zoom (Essen BioScience,
Ann Arbor, MI, http://www.essenbioscience.com) every 3 hours
for 4 days without media change. Alternatively, imaging was performed by using an inverted fluorescence microscope (Nikon)
with images captured using a Sony XC-77 camera (Sony, Tokyo,
Japan, http://www.sony.com). In addition, we used laser-scanning
cytometry to interrogate large numbers of cells [25].
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Quantitative PCR Analysis
Total RNA was isolated by using SpinSmart RNA Mini Purification Kit (Denville Scientific Inc., Metuchen, NJ, https://www.
denvillescientific.com). One microgram of RNA was reverse transcribed by using a High Capacity RNA-cDNA kit (Thermo Fisher).
Real-time quantitative PCR was performed by using Perfecta SYBR
Green FastMix on a Stratagene MX3000P (Thermo Fisher).
The following primers were used: COL1-FOR primer 59CTG CTG
GCA AAG ATG GAG A39 and COL1-REV primer 59ACC AGG AAG ACC
CTG GAA TC39; COL3-FOR primer 59 CAA ATG GCA TCC CAG GAG39
and COL3-REV primer 59CAT CTC GGC CAG GTT CTC 39; a-SMA-FOR
primer 59AGC GTG AGA TTG TCC GTG ACA T39 and a-SMA-REV
primer 59 GCG TTC GTT TCC AAT GGT GA39; VE-cadherin-FOR primer
59ACC ATC GCC AAA AGA GAG AC39 and VE-cadherin-REV primer
59TCT TGC CAG CAA ACT CTC CT39; CD31-FOR primer 59AGC GCA
GTC TTA CCG AAG G39; CD31-REV primer 59TCT TGC CAG CAA
ACT CTC CT39; Oct4–FOR primer CAAGGCAAGGGAGGTAGACA;
REV primer GCTCCTGATCAACAGCATCA; KLF4 – FOR primer CCAGCAAGTCAGCTTGTGAA; REV primer GGGCATGTTCAAGTTGGATT;
c-Myc – FOR primer GCCTAACCTCACAACCTTGG; REV primer
CCTATTTACATGGGAAAATTGGA; Nanog – FOR primer AGCCTCCAGCAGATGCAAGA; and REV primer GCACTTCATCCTTTGGTTTTGA. Values were normalized for the abundance of the amplified 18s rRNA in
each experiment. Fold change in gene expression was determined
by using the 2-DDCT method.

Statistical Analysis
All experiments were repeated at least three times. Data were analyzed using NCSS9 (NCSS Statistical Software, Kaysville, Utah;
http://www.ncss.com) and are expressed as mean 6 SEM. The
data were examined by using analysis of variance with the Bonferroni post hoc test, Mann-Whitney test, or Kruskal-Wallis test.
p , .05 was considered to represent statistically significant
differences.

RESULTS
Effects of EPC Extract on Fibroblast-toMyofibroblast Transition
We cultured 3T3 fibroblasts in fibroblast medium and EBM2 endothelial medium; cells were permeabilized and treated with EPC extract.
Only the combination of endothelial-specific medium and EPC extract
was sufficient to change the morphologic features of cultured fibroblasts into cells self-organizing into a capillary-like web (supplemental
online Fig. 1) within 28 days of such a treatment. In view of the prior
evidence of fibroblast reprogramming into endothelial cells [26], we
next examined the expression of endothelial markers (VE-cadherin)
in cultured fibroblasts exposed to EPC extract. Despite the ability
of these cells to form capillary-like tubes, the expression of endothelial markers was marginal, thus calling into question their
reprogramming toward endothelial lineage. Immunohistochemical characterization of the treated cells, however, showed
a significant reduction in a-SMA staining (supplemental online
Fig. 2). In addition, we attempted to reproduce effects of the
EPC extract by using similarly prepared extract of mature endothelial cells. This procedure failed to appreciably change the phenotype of fibroblasts and reproduce the results obtained with the
EPC extract (data not shown).
When fibroblasts were derived from a-SMA-GFP mouse kidneys (or NIH 3T3 fibroblasts used interchangeably), cells initially
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showed marginal expression of GFP (Fig. 1A), but the proportion
of GFP-positive cells increased dramatically after TGF-b1 treatment.
Under these conditions, when cells also received EPC extract
through use of the permeabilization protocol, their conversion to
a-SMA-positive myofibroblasts was significantly halted. We performed 96-hour time-lapsevideomicroscopy of fibroblasts obtained
from a-SMA-GFP mouse kidneys and omitted prior cell permeabilization. Under control conditions, approximately 20% of cells
exhibited expression of GFP fluorescence. In contrast, nearly 80% of
TGF-b-treated fibroblasts acquired GFP fluorescence within 24–48
hours (Fig. 1B). Cotreatment with the EPC extract resulted in approximately 33% of fibroblasts gaining GFP fluorescence (i.e., halting
fibroblast-to-myofibroblast transition by nearly 50%). Without
TGF-b1 pretreatment, effects of the EPC extract alone were minimal
or undetectable, suggesting that the TGF-b1-induced activation of
fibroblasts could be abrogated by the EPC extract. Charted fluorescence intensity is summarized in Figure 1B. Collectively, these findings
suggested modulation of fibroblast cell fate by the EPC extract.

In Vivo Effects of EPC Extract in Models of Renal Fibrosis
Unexpectedly, the EPC extract-mediated inhibition of TGF-b1induced phenotypic changes did not require prior cell permeabilization, as shown in data presented in Figure 1B. This raised the
question: Is the effect of EPC extract mediated via (a) changes in
the extracellular environment, (b) receptor-mediated signaling by
the components of the extract, or (c) temporary spontaneous
permeabilization of the plasma membrane in the course of transition from a fibroblast to a myofibroblast? In fact, mechanically
active cells undergo transient permeabilization [27, 28], thus
buttressing the third explanation while not rejecting the former
ones (see following discussion). Collectively, these studies have
established the possibility of preventing in vitro TGF-b1induced fibroblast activation and acquisition of the myofibroblastic phenotype using EPC extract treatment of nonpermeabilized
cells and raised the possibility of transcendence of this effect
to an in vivo setting.
In the light of potential therapeutic significance of the preceding in vitro observation that EPC extract-mediated prevention of
fibroblast-to-myofibroblast transition can be achieved without
prior cell permeabilization, we next attempted to test this effect
in vivo. We argued that cell permeabilization could be omitted
because even under physiologic conditions diverse cells undergo this process, especially in a mechanically active microenvironment [27, 28]. Indeed, when 5 days after UUO kidneys were
injected subcapsularly with 70 kD Texas red dextran, the agent was
readily detectable in the renal parenchyma of the UUO but not the
contralateral kidney 1 hour after the injection (supplemental online
Fig. 3).
On the basis of these findings, we next performed UUO, the
standard model of renal fibrosis, and injected the affected kidney
with EPC extract or the vehicle. Subcapsular injection of the EPC
extract into UUO kidneys was associated with the nearly 50% reduction of renal fibrosis (Fig. 2A). The number of myofibroblasts
was reduced by 35% and CD31-positive area was increased by
35% compared with those in vehicle-treated mice (Fig. 2B). EPC
extract treatment was also associated with the reduction of macrophage infiltration of UUO kidneys (supplemental online Fig. 4).
Considering the breadth of EPC extract effects, it appears less
likely that its observed actions were mediated via myofibroblast
permeabilization.
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Figure 1. Immunocytochemical detection of a-SMA in National Institutes of Health 3T3 cells (n = 3) (A) and time-lapse videomicroscopy images
of a-SMA-GFP-positive fibroblasts (B) after activation with TGF-b1 in the presence of EPC extract or LIF (vide infra). p, p , .05 versus control;
†, p , .05 versus TGF-b1. Original magnification, 340. Scale bars = 25 mm. Data on time-lapse videomicroscopy is representative of two independent experiments. Abbreviations: a-SMA, a-smooth muscle actin; EPC, endothelial progenitor cell; GFP, green fluorescent protein; LIF,
leukemia inhibitory factor; TGF-b1, transforming growth factor-b1.

In another model of renal fibrosis, the chronic phase of folic
acid-induced nephropathy, a-SMA-GFP transgenic mice were injected intraperitoneally with folic acid (250 mg/kg) on day 0. EPC
extract (10 ml) was injected subcapsularly in left kidneys and
the vehicle (10 ml) was injected in right kidneys on day 56 after
the induction of folic acid nephropathy. Notably, at this time,
post-folic acid induction renal fibrosis becomes readily detectable [29]. Mice were sacrificed 3 months after initiation of folic

acid-induced nephropathy. As summarized in Figure 3, this delayed
treatment with EPC extract resulted in a remarkable reversal of
renal fibrosis. Hence, the in vivo data demonstrated that (a)
the effect of EPC extract is not limited to the UUO model
and (b) the EPC extract is capable of not only preventing but
also reversing established tubulointerstitial fibrosis. Remarkably, the amelioration of renal fibrosis was associated with the restoration of microvascular density. It is doubtful, however, that this
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Figure 2. Endothelial progenitor cell extract reduces fibrosis in UUO kidney. EPC extract was injected subcapsularly, as detailed in Materials and Methods.
(A):Renalhistology onday14invehicle-treatedandEPCextract-treatedkidneys.Originalmagnification,310, 340.(B):Quantitativeassessmentofinterstitial
fibrosis in each group. Each group contained seven mice, and five fields per mice were evaluated in a blinded to the source manner. Data are expressed as
mean 6 SEM (Kruskal-Wallis test). pp, p , .01 versus UUO mice with the same duration of vehicle treatment. (C): Subcapsular injection of EPC extract to UUO
kidneys reduced the number of a-SMA-GFP-positive cells and improved the density of peritubular capillaries. p, p , .05. Scale bars = 400 and 100 mm (A) and
100 mm (C). Abbreviations: a-SMA, a-smooth muscle actin; EPC, endothelial progenitor cell; NS, not significant; UUO, unilateral ureteric obstruction.
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Figure 3. Subcapsular injection of EPC extract into kidneys with folic acid-induced nephropathy resulted in a significant reversal of fibrosis.
Masson’s trichrome staining of kidney sections, and analysis of blue pixels. n = 3. p, p , .05. Right lower panel shows the chronological relations
between the initiation of disease (folic acid injection), subcapsular injection of the EPC extract, and the termination of the experiment. Abbreviation: EPC, endothelial progenitor cell.

finding is due to the reversal of endothelial-mesenchymal transition because we were unable to detect endothelial markers in cultured fibroblasts treated with the EPC extract. It is consistent,
however, with the previous reports on the proangiogenic effect
of fibroblasts [30, 31].

Cytokine and Chemokine Screen of EPC Extract Revealed
LIF as a Putative Effector
We next inquired what components of EPC extract could mediate
the observed effects. Multiplex analysis of EPC extract showed
that it was dramatically enriched in LIF and VEGF, much above
other cytokines and chemokines (Fig. 4A). Notably, the elevation
of LIF was unique to these cells, as our previous studies did not
detect it in these amounts in the conditioned media of mesenchymal stem cells or macrophages [32]. Moreover, recent proteomic
studies of endothelial cell secretome did not detect prodigious
amounts of LIF (manuscript in preparation). These findings raised
the possibility that LIF and VEGF could be responsible for the observed actions of EPC extract. Of note, the previous study of the
transcriptome of these EPC revealed upregulation of these messages [33]. When we substituted EPC extract in the cell treatment
protocol with LIF or VEGF, only LIF (100 pg/ml, the concentration
similar to that seen in the extract) was able to mimic the effect of
the EPC extract in halting conversion to myofibroblasts (Figure 1B
and data not shown). The effect of LIF in preventing formation of
myofibroblasts was evident after 24 hours but dissipated at later
times. These in vitro findings of effects of EPC extract components
led to attempts to reproduce these results in vivo. Injection of LIF
to UUO kidney (100 pg LIF/kidney in 10 ml of PBS), at the time of
the surgery or 1 week after the surgery, resulted in the substantially reduced number of a-SMA-GFP cells by LIF injection to UUO
kidneys (Fig. 4B), and microvascular rarefaction, a hallmark of
UUO, was significantly prevented (Fig. 4C). In contrast to this,

injection of LIF did not result in any appreciable decline in the degree of fibrosis commensurate with that seen upon injection of
EPC extract. The similar lack of antifibrotic effect of LIF alone
was detected in the chronic phase (3 months after induction)
of the folic acid nephropathy model (supplemental online Fig. 5).
These findings raise the possibility of dissociation between
myofibroblastogenesis and the degree of fibrosis, at least
within the timeframe of current experiments.

Therapeutic Induction of gp130-STAT3 Pathway
Mitigated Fibrosis
To unravel the apparent lack of antifibrogenic in vivo LIF effect, we
recreated the experiment in vitro and examined the expression of
known downstream targets of LIF/gp130 signaling via STAT3
(Klf-4, c-Myc, Oct4, and Nanog [34–36]). We used primary cultures of renal fibroblasts that showed a high degree of purity
and no endothelial contamination (Fig. 5A). We first confirmed
STAT3 activation in these cells. LIF resulted in a fast wave of STAT3
phosphorylation (Fig. 5B). A similar STAT3 phosphorylation was
achieved by using a receptor-independent gp130 ligand, a fusion
protein hyper-IL-6 [37] (Fig. 5C), consisting of IL-6 fused via a 40-Å
linker to the soluble extracellular portion of the IL-6 receptor.
Quantitative PCR analysis of transcription factors (Fig. 6) showed
that at 12 and 24 hours after administration of LIF or hyper-IL-6,
the abundance of message for Nanog and c-Myc was elevated and
coapplication of LIF or hyper-IL-6 with TGF-b1 resulted in a further
increase of mRNA encoding these transcription factors within the
preceding time frame. In the case of c-Myc, induction was significantly more pronounced at 12 hours after application of hyper-IL-6.
These findings suggest the acquisition by myofibroblasts of transient pluripotency induced by gp130/STAT3 activation.
To resolve uncertainty related to changes in Oct4, we next performed experiments in Oct4-GFP-reporter fibroblasts obtained
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Figure 4. LIF abundance in the EPC extract and its actions in vivo. (A): Results of the multiplex analysis of the abundance of different cytokines and
chemokines in the EPC extract (triplicate samples). Results are compared with the nonconditioned medium. (B): The number of a-smooth muscle
actin (a-SMA)-green fluorescent protein-positive cells is reduced (top left) and the density of peritubular capillaries is increased (top right), but
fibrosis remains unchanged in kidneys of mice with UUO (lower left), which received subcapsular injection of LIF, compared with the vehicle alone
(n = 4–6 mice per group). In lower right, quantitative reverse-transcriptase polymerase chain reaction data on the abundance of a-SMA and collagen
I are consistent with morphologic findings. p, p , .05. Scale bars = 100 mm. Abbreviations: EPC, endothelial progenitor cell; G-CSF, granulocyte
colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; IP, inducible protein; KC,
keratinocyte chemoattractant; LIF, leukemia inhibitory factor; MIP, macrophage inflammatory protein; PBS, phosphate-buffered saline; RANTES,
regulated on activation, normal T-cell expressed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.

from transgenic mice expressing tamoxifen-inducible Cre recombinase MerCreMer under the control of the endogenous Oct4
locus developed by Dutton’s group [21]. Under basal conditions
with tamoxifen application only, GFP fluorescence was nearly undetectable in a large cohort of cells examined by using laser scanning cytometry (Fig. 6B). Both LIF and hyper-IL-6 resulted in a
moderate induction of Oct4-GFP, as did TGF-b alone. However, only
application of TGF-b in combination with LIF and, to a higher degree,
hyper-IL-6 produced 1/5-1/4 conversion to Oct4-expressing cells.
We next inquired whether treatment of myofibroblasts with
LIF or hyper-IL-6 could reverse myofibroblasts to fibroblasts. To
address this possibility, we cultured primary renal fibroblasts isolated from a-SMA-GFP mice on Matrigel-coated plastic (Corning
Inc., Corning, NY, http://www.corning.com) for 96 hours and

induced myofibroblastic transition by adding TGF-b1 (5 ng/ml)
to cultured cells. After 48 hours, when the proportion of myofibroblasts increased significantly, as judged by the enhancement
of a-SMA-GFP fluorescence. As summarized in Fig. 6C, at 72 hours
there was no statistically significant difference in fluorescence intensity between cells subjected to TGF-b1 alone or in combination with LIF or hyper-IL-6; however, at 96 hours, fluorescence
intensity of a-SMA-GFP was significantly reduced in the treated
groups. The data suggest the possibility of myofibroblast-tofibroblast transition induced by LIF or hyper-IL-6.
On the basis of these findings, we next examined the in vivo effect of hyper-IL-6 in the model of chronic folic acid-induced nephropathy (the duration of this model allows for the delayed institution of
treatments). As shown in Figure 7A, renal subcapsular injection of
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Figure 5. Effects of LIF and hyper-IL-6 on STAT3 phosphorylation in primary cultures of renal fibroblasts. (A): Immunocytochemical demonstration of the purity of renal fibroblast cultures devoid of CD31-positive and containing only rare F4/80-positive cells (a bright-field image is
presented in the center panel). (B): LIF-induced phosphorylation of STAT3. (C): Hyper-IL-6-induced phosphorylation of STAT3 in the presence or
absence of TGF-b1. Note that maximal effect is achieved when both hyper-IL-6 and TGF-b1 are applied. LIF was used at the concentration of 100
pg/ml, hyper-IL-6 at 10 ng/ml; n = 3–4 per group. Abbreviations: aSMA; a-smooth muscle actin; Ctrl, control; IL, interleukin; LIF, leukemia inhibitory factor; PDGFRb, platelet-derived growth factor receptor b.

hyper-IL-6 1 week after induction of nephropathy resulted in a dramatic dose-dependent prevention of fibrosis 3 months later (using
100 ng hyper-IL-6 per injected kidney, but not 10 ng). This effect
was associated with a significant decline in the number of a-SMApositive fibroblasts (Fig. 7C, 7D). Quantitative PCR analysis of the kidneys showed the reduction of collagen I and III transcripts (Fig. 7E).

DISCUSSION
The data presented herein show that cell-free extract of endothelial progenitor cells, but not the extract of mature endothelial
cells, reprograms kidney-derived and 3T3 fibroblasts to prevent
their TGF-b1-induced acquisition of myofibroblastic phenotype
in culture. Moreover, extracts obtained from endothelial progenitors and injected into fibrotic kidneys ameliorate development of
fibrosis. LIF and VEGF, both highly expressed in the extract of endothelial progenitors, were tested in in vitro reprogramming of
myofibroblasts and only LIF was found to be effective. However,
it was not sufficient to affect the course of fibrotic disease in vivo,
probably indicating that additional reprogramming factors, either
exogenous or endogenous, are necessary for antifibrogenic activity of the EPC extract. Nonetheless, LIF administration in vivo in
two different models of nephrosclerosis curtails myofibroblastic
transformation in a way similar to in vitro data. Induction of STAT3
pathway and pluripotency transcription factors were incriminated in the effect of LIF on primary fibroblasts. Another,
receptor-independent, ligand of gp130, hyper-IL-6, more robustly
induces STAT3 and pluripotency transcription factors Oct4, KLF4,
and c-Myc. In vivo, renal subcapsular injection of hyper-IL-6 exhibits a profound antifibrotic effect. Thus, commencing with
the cell extract and observing its antifibrotic action, studies progressed toward identification of an active component of the extract, LIF, which partially mimics the effect of the extract; the
studies evolved to a more potent gp130 ligand, hyper-IL-6, to disclose its robust antifibrotic effect in the kidney.
The previously held views of cell-autonomous mechanisms defining its fate and state of differentiation have recently been challenged,
thus bringing to the fore the mechanisms of cell-cell communication

and the instructive role of the microenvironment [38–40]. Conversion of adoptively transferred mesenchymal stem cells into endothelial cells in the ischemic heart has been described [41].
Nanofibers preconditioned with embryonic stem cell secretome
and injected into injured kidney have a renoprotective effect [42].
Hence, the long-term objective of our studies is to define the active components of the EPC extract that could mimic its antifibrotic properties. The first in a series screen of the EPC extract
detecting cytokines and chemokines reveals that it is highly
enriched in LIF and VEGF.
Indeed, application of LIF alone to TGF-b1-stimulated cultured fibroblasts prevented and reversed their transition to myofibroblasts. In in vivo experiments using two distinct models of
tubulointerstitial fibrosis, LIF again prevented accumulation of
myofibroblasts; however, it failed to prevent development of fibrosis. LIF/gp130/STAT3 pathway is known to be sufficient to
maintain an undifferentiated state of mouse embryonic stem cells
[43]. LIF has been found to control dedifferentiation of embryonic epiblasts to inner cell mass-like cells [44] and is routinely used in mouse
reprogramming media [45]. Survival of cardiomyocytes and cardiac regeneration are enhanced by LIF [46]. Most recently, LIF has been
shown to attenuate renal fibrosis [47], but daily injections are required. Our own data demonstrate that LIF not only is highly enriched
in EPC extract but possesses anticontractile functions, without perturbing matrix synthesis in TGF-b1-stimulated fibroblasts. Admittedly, our data do not cover the broad range of possible
doses and regimens of administration. This dichotomy is consistent with the separate regulatory mechanisms for a-SMA and
collagen 1 synthesis by TGF-b1-stimulated fibroblasts.
It is curious that the therapeutic prevention and reversal of
fibroblast-to-myofibroblast transition do not require cell permeabilization. There is growing awareness, based on a series of studies from McNeil and Steinhardt [27, 28], of spontaneous bouts of
permeabilization of the plasma membrane occurring in most
cells, but mechanically active cells have a much higher probability
of permeabilization. This is precisely the case with the contractile
cells, such as myofibroblasts, which become readily loaded with
the 70-kD dextran, whereas interstitial fibroblasts (which are less
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Figure 6. Analysis of pluripotency transcription factors Nanog and c-Myc after application of LIF or hyper-IL-6 in the presence or absence of TGFb1 and myofibroblast-to-fibroblast transition induced by LIF and hyper-IL-6. (A): Results of quantitative polymerase chain reaction. After 24
hours, only c-Myc and Nanog showed significant differences (Oct4 and Klf4 are not shown). Horizontal lines, statistically significant differences
between the groups (p , .05). (B): Laser scanning cytometry [25] data obtained in two separate experiments, each in duplicate, using Oct4-GFP
reporter fibroblasts. (C): Box-and-whiskers plot of myofibroblast-to-fibroblast transition induced by LIF and hyper-IL-6. Primary renal fibroblasts
isolated from a-smooth muscle actin (a-SMA)-green fluorescent protein (GFP) mice were cultured on Matrigel-coated plastic dishes for 96
hours. TGF-b1 (5 ng/ml) induced myofibroblastic transition after 48 hours. By 96 hours, fluorescence intensity of a-SMA-GFP was significantly
reduced in LIF- and hyper-IL-6-treated groups (n = 4 each). p, p , .05, Kruskal-Wallis test. Abbreviations: Ctrl, control; eGFP, enhanced green
fluorescent protein; H/T, hyper-interleukin-6–transforming growth factor-b1; hyper-IL-6; hyper-interleukin-6; LIF, leukemia inhibitory factor;
L/T, leukemia inhibitory factor–transforming growth factor-b1; TGF-b1, transforming growth factor-b1.
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Figure 6. Continued from previous page.

active mechanically) are not. This fact alone makes myofibroblasts
selectively amenable for therapeutic targeting without prior permeabilization and offers facile technical advantages over other
reprogramming techniques, such as cell fusion and induction with
transcription factors or small molecules, which lack cell-type tropism. Whether this particular mechanism plays a critical role in

the panoply of observed actions remains questionable because
some of these effects are LIF-receptor-mediated whereas others
that bypass the receptors and activate the gp130/STAT3 pathway,
such as hyper-IL-6, do not require the permeabilization step.
Endothelial-mesenchymal transition is a physiological developmental process of embryogenic formation of heart valves and
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Figure 7. Intrarenal injection of hyper-IL-6 results in a dose-dependent amelioration of renal fibrosis (A, B), reduction in the number of a-smooth
muscle actin-positive cells (C, D), and mRNA encoding col I and III (E) in the FA-induced nephropathy. Data are the mean 6 SEM of n = 3–5.
Lines, p , .05. Scale bar = 100 mm (A). Abbreviations: Col, collagenase; Ctrl; control; FA, folic acid; H10ng, hyper-IL6 10 ng; H100ng, hyper-IL6
100 ng; PBS, phosphate-buffered saline.
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septa, but some investigators argue that in adulthood this transition is a major contributor to vascular dropout and development
of tubulointerstitial fibrosis [15, 48, 49]. From 30% to 50% of interstitial fibroblasts in fibrotic renal disease models originate
from the endothelium. Although our original hypothesis has been
based on the possibility of EPC extract-induced transdifferentiation
of myofibroblasts toward endothelial lineage, the data obtained
are more consistent with the conversion of myofibroblasts into fibroblasts. In fact, such a myofibroblast-to-fibroblast conversion
has been previously described [50], and it has been shown that amniotic membrane stromal extract can actuate this reversal [51].
Nevertheless, administration of the EPC extract was accompanied
by improvement in microvascular density, but this effect does not
appear to be secondary to mesenchymal-endothelial transition;
rather, it is most likely attributed to the fibroblast-promoted angiogenesis, as previously demonstrated [30, 31].
The finding that LIF and, to a greater extent, hyper-IL-6 activate gp130/STAT3 pathway with the subsequent induction of
pluripotency factors (c-Myc, Nanog, and later Oct4) raises the
possibility of the acquisition of a transitional stage during reversal
of myofibroblasts to fibroblasts via a ground-state of a pluripotent
cell. It is not excluded that, given the proper differentiation cues,
such cells may differentiate toward diverse lineages. In fact, more
than 2 decades ago Kato and Gurdon [52] established that
Xenopus egg cytoplasm has a capacity for reprogramming somatic
cell nuclei. Although this line of evidence would support the idea of
reprogramming of our myofibroblasts by EPC extract, it is not necessarily the only pathway for the observed effect of hyper-IL-6,
which is believed to rely entirely on the gp130 signaling. It is noteworthy that, when this article was in preparation, a transient acquisition of pluripotency during transdifferentiation of somatic cells
with a mixture of transcription factors was described as a hallmark
of reprogramming [53, 54]. In the context of our study, the similar
conclusion can be reached when reprogramming is conducted via
activation of gp130/STAT3 pathway rather than by supplying the
downstream transcription factors. It is also remarkable that two
known antifibrogenic strategies, IL-10 and interferon-g, both activate
the gp130/STAT3 pathway to achieve this effect [55, 56]. Certainly,
fate-mapping studies will be required in the future to monitor the trajectory of myofibroblasts in fibrotic kidneys treated with hyper-IL-6.
Nonetheless, the very finding of induction of the pluripotency transcription factors, albeit in vitro, argues strongly in favor of transient
pluripotency as a potentially notable contributor to reprogramming.

CONCLUSION
EPC extract prevents and reverses fibroblast-to-myofibroblast transition and renal fibrosis. The component of EPC extract, LIF, is capable of preventing development of the contractile phenotype of
activated fibroblasts but does not eliminate TGF-b1-induced collagen synthesis in cultured fibroblasts and renal fibrosis. Unquestionably, this component of EPC extract is a participant in its antifibrotic
effect, but not the sole one, as other yet-undisclosed factors may
contribute to the antifibrotic effect of the extract. These findings
should stimulate future identification and in-depth characterization
of such components. On the other hand, a receptor-independent
inducer of gp130/STAT3 pathway, hyper-IL-6, is capable of consistently inducing in vitro pluripotency transcription factors, Nanog
and c-Myc, and later on Oct4, and preventing renal fibrosis in vivo.
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